We are cultivating a differentiated pipeline of small molecule medicines that utilize first-in-class or potential best-in-class mechanisms of action (MoAs) to restore balance in the brain by reducing the neuronal hyperexcitability that underlies debilitating brain conditions. Our unique understanding of the complexities of neurologic systems allows us to turn preclinical potential into clinical meaning.

Our aim is to make a meaningful impact and address the significant unmet need in the lives of individuals with epilepsies and neurological disorders that present with brain conditions.

Publications and Posters ยป

Programs Indication opportunities Preclinical Phase 1 Phase 2
+
 		OV329

GABA-aminotransferase inhibitor

Drug resistant adult epilepsies (DREs) & developmental epileptic encephalopathies (DEEs)
+
 		KCC2 direct activator portfolio

OV350 IV

Proof of mechanism

OV4071 oral

Psychosis assoc. with Parkinson's disease and Lewy body dementia

OV4041 oral

Generalized anxiety disorder or Rett syndrome

Drug Indication Stage
OV329

GABA-aminotransferase inhibitor

Drug resistant adult epilepsies (DREs) & developmental epileptic encephalopathies (DEEs)

Phase 1: Oral
KCC2 direct activator portfolio

OV350 IV

Proof of mechanism

End of Preclinical: IV

OV4071 oral

Psychosis assoc. with Parkinson's disease and Lewy body dementia

Preclinical: oral

OV4041 oral

Generalized anxiety disorder or Rett syndrome

Preclinical: oral

Ovid has a Phase 2-ready ROCK2 inhibitor, OV888, in collaboration with Graviton Bioscience. This program was cleared by regulators to initiate Phase 2 but is currently paused while Ovid monitors the outcome of regulatory interactions by competitors.